Literature DB >> 3129192

Role of proliferation in LAK cell development.

F J Ramsdell1, H Shau, S H Golub.   

Abstract

Lymphokine-activated killer (LAK) cell activity may be largely the result of activation and/or expansion of peripheral blood natural killer cells by culture with interleukin-2 (IL-2). We have examined the role of proliferation in LAK cell development by either inhibiting or enhancing the proliferative potential of peripheral blood lymphocytes. Inhibition of proliferation was accomplished using irradiation, mitomycin C, or the iron chelator deferoxamine. For each of these agents, a dose-dependent inhibition of proliferation was observed. At doses of inhibitor which nearly completely blocked thymidine uptake, the development of LAK activity was only partially impaired. The mitogenic lectins phytohemagglutinin (PHA) and concanavalin A (Con A) augmented the proliferative response of peripheral blood lymphocytes to IL-2. However, augmentation by PHA, but not Con A, consistently resulted in a decrease in LAK activity. This inhibition of LAK activity by PHA did not appear to be due to inhibition of the effector cell, nor to preferential expansion of irrelevant cells. These data suggests that not all LAK activity is dependent on proliferation, and that high levels of proliferation in the presence of IL-2 do not necessarily lead to LAK activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129192     DOI: 10.1007/bf00205607

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.

Authors:  V J Merluzzi; P A Trail; K Last-Barney
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

2.  The functional capacity of thymus subpopulations: limit-dilution analysis of all precursors of cytotoxic lymphocytes and of all T cells capable of proliferation in subpopulations separated by the use of peanut agglutinin.

Authors:  C Wei-Feng; R Scollay; K Shortman
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

3.  Precursor phenotype of lymphokine-activated killer cells in the mouse.

Authors:  R R Salup; B J Mathieson; R H Wiltrout
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

4.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

5.  Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells.

Authors:  H Shau; S H Golub
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

6.  Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.

Authors:  Y Kaufmann; M Levanon; J Davidsohn; B Ramot
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

7.  Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. II. Regulatory role of interferon on proliferative and cytotoxic precursors.

Authors:  B M Vose; C Riccardi; G D Bonnard; R B Herberman
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

8.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  9 in total

1.  Extended analysis of the in vitro tropism of porcine endogenous retrovirus.

Authors:  C A Wilson; S Wong; M VanBrocklin; M J Federspiel
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors.

Authors:  A A Maghazachi
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

3.  The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity.

Authors:  Y Tokuda; N Ebina; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Interleukin-2-induced lymphoproliferative responses.

Authors:  A Winkelstein; L D Weaver; N Salva; L L Machen
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  The effects of staphylococcal protein A on human lymphokine-activated killer cell induction.

Authors:  R A Lindemann; K P Singh; H Shau; R K Gupta
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor.

Authors:  H Hirte; D A Clark
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity.

Authors:  N Ebina; D Gallardo; H Shau; S H Golub
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

9.  Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

Authors:  A von Rohr; A K Ghosh; N Thatcher; P L Stern
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.